Aura Biosciences, Inc.

AURANASDAQHealthcare● Active

$6.48

$-0.15(-2.27%)

Market Cap$415976029

P/E Ratio—

52W High$9.535

52W Low$4.73

Avg Volume476K

Open$6.73

Beta0.39

Overview

Aura Biosciences, Inc. (AURA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · AURA · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Aura Biosciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

AURA insider buying and selling by quarter

AURA insider selling · AURA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

6.9M3.5M0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · AURA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

AURA executive sell shares · AURA board member insider trading · AURA insider trading SEC filing

Showing 58 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 19, 2026	Holles Natalie C. See Remarks · Director	Award	553,844	—	—	1,153,962	Form 4
May 19, 2026	Holles Natalie C. See Remarks · Director	Award	600,118	—	—	600,118	Form 4
Apr 16, 2026	Kilroy Conor See Remarks	Sale	11,738	$7.02	$82K	217,835	Form 4
Mar 2, 2026	Kilroy Conor See Remarks	Award	62,339	—	—	229,573	Form 4
Mar 2, 2026	Gibney Anthony S See Remarks	Award	71,245	—	—	278,178	Form 4
Mar 2, 2026	de los Pinos Elisabet See Remarks · Director	Award	166,000	—	—	575,815	Form 4
Mar 2, 2026	Plavsic Mark CTO	Award	62,339	—	—	243,736	Form 4
Mar 2, 2026	Hopkins Janet Jill Chief Medical Officer	Award	89,056	—	—	321,340	Form 4
Mar 2, 2026	Elazzouzi Amy Senior Vice President, Finance	Award	44,528	—	—	120,060	Form 4
Feb 17, 2026	Kilroy Conor See Remarks	Sale	12,079	$5.05	$61K	167,234	Form 4
Feb 17, 2026	Plavsic Mark CTO	Sale	15,890	$5.05	$80K	181,397	Form 4
Feb 17, 2026	Hopkins Janet Jill Chief Medical Officer	Sale	20,401	$5.06	$103K	232,284	Form 4
Feb 17, 2026	Elazzouzi Amy Senior Vice President, Finance	Sale	8,549	$5.06	$43K	75,532	Form 4
Feb 17, 2026	de los Pinos Elisabet See Remarks · Director	Sale	47,648	$5.06	$241K	409,815	Form 4
Jan 20, 2026	Elazzouzi Amy Senior Vice President, Finance	Sale	1,581	$4.86	$8K	84,081	Form 4
Jan 20, 2026	de los Pinos Elisabet See Remarks · Director	Sale	16,928	$4.86	$82K	457,463	Form 4
Nov 17, 2025	Hopkins Janet Jill Chief Medical Officer	Sale	17,109	$5.42	$93K	252,685	Form 4
Oct 29, 2025	Elazzouzi Amy Senior Vice President, Finance	Sale	896	$6.35	$6K	85,662	Form 4
Oct 29, 2025	de los Pinos Elisabet See Remarks · Director	Sale	9,049	$6.35	$57K	474,391	Form 4
Oct 16, 2025	Plavsic Mark CTO	Sale	12,169	$6.35	$77K	197,287	Form 4
Aug 18, 2025	Elazzouzi Amy Senior Vice President, Finance	Option	2,319	$4.25	$10K	94,280	Form 4
Aug 18, 2025	Elazzouzi Amy Senior Vice President, Finance	Option	1,094	$3.16	$3K	91,961	Form 4
Aug 18, 2025	Elazzouzi Amy Senior Vice President, Finance	Option	4,744	$2.74	$13K	90,867	Form 4
Aug 18, 2025	Elazzouzi Amy Senior Vice President, Finance	Sale	7,722	$6.70	$52K	86,558	Form 4
Aug 18, 2025	Elazzouzi Amy Senior Vice President, Finance	Option	547	$5.21	$3K	86,123	Form 4

Holles Natalie C.

See Remarks · Director

Award

Date

May 19

553,844

Price

—

Value

—

View Form 4 on SEC.gov

Holles Natalie C.

See Remarks · Director

Award

Date

May 19

600,118

Price

—

Value

—

View Form 4 on SEC.gov

Kilroy Conor

See Remarks

Sale

Date

Apr 16

11,738

Price

$7.02

Value

$82K

View Form 4 on SEC.gov

Kilroy Conor

See Remarks

Award

Date

Mar 2

62,339

Price

—

Value

—

View Form 4 on SEC.gov

Gibney Anthony S

See Remarks

Award

Date

Mar 2

71,245

Price

—

Value

—

View Form 4 on SEC.gov

de los Pinos Elisabet

See Remarks · Director

Award

Date

Mar 2

166,000

Price

—

Value

—

View Form 4 on SEC.gov

Plavsic Mark

CTO

Award

Date

Mar 2

62,339

Price

—

Value

—

View Form 4 on SEC.gov

Hopkins Janet Jill

Chief Medical Officer

Award

Date

Mar 2

89,056

Price

—

Value

—

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Award

Date

Mar 2

44,528

Price

—

Value

—

View Form 4 on SEC.gov

Kilroy Conor

See Remarks

Sale

Date

Feb 17

12,079

Price

$5.05

Value

$61K

View Form 4 on SEC.gov

Plavsic Mark

CTO

Sale

Date

Feb 17

15,890

Price

$5.05

Value

$80K

View Form 4 on SEC.gov

Hopkins Janet Jill

Chief Medical Officer

Sale

Date

Feb 17

20,401

Price

$5.06

Value

$103K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Sale

Date

Feb 17

8,549

Price

$5.06

Value

$43K

View Form 4 on SEC.gov

de los Pinos Elisabet

See Remarks · Director

Sale

Date

Feb 17

47,648

Price

$5.06

Value

$241K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Sale

Date

Jan 20

1,581

Price

$4.86

Value

$8K

View Form 4 on SEC.gov

de los Pinos Elisabet

See Remarks · Director

Sale

Date

Jan 20

16,928

Price

$4.86

Value

$82K

View Form 4 on SEC.gov

Hopkins Janet Jill

Chief Medical Officer

Sale

Date

Nov 17

17,109

Price

$5.42

Value

$93K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Sale

Date

Oct 29

896

Price

$6.35

Value

$6K

View Form 4 on SEC.gov

de los Pinos Elisabet

See Remarks · Director

Sale

Date

Oct 29

9,049

Price

$6.35

Value

$57K

View Form 4 on SEC.gov

Plavsic Mark

CTO

Sale

Date

Oct 16

12,169

Price

$6.35

Value

$77K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Option

Date

Aug 18

2,319

Price

$4.25

Value

$10K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Option

Date

Aug 18

1,094

Price

$3.16

Value

$3K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Option

Date

Aug 18

4,744

Price

$2.74

Value

$13K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Sale

Date

Aug 18

7,722

Price

$6.70

Value

$52K

View Form 4 on SEC.gov

Elazzouzi Amy

Senior Vice President, Finance

Option

Date

Aug 18

547

Price

$5.21

Value

$3K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About AURA insider trading

AURA insider trades

Aura Biosciences, Inc. (AURA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Elazzouzi Amy (Senior Vice President, Finance), de los Pinos Elisabet (See Remarks · Director), Kilroy Conor (See Remarks). Over the past 12 months, 5 insiders have filed transactions with the SEC. AURA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Aura Biosciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

AURA insider trading · 5 questions

The insiders of Aura Biosciences, Inc. (AURA) include executives and directors such as Elazzouzi Amy (Senior Vice President, Finance), de los Pinos Elisabet (See Remarks · Director), Kilroy Conor (See Remarks), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

AURA board member insider tradingwho are AURA insidersAURA insider rosterAura Biosciences, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026